Leukemia supplements最新文献_第3页

Stem cell transplantation for multiple myeloma: current and future status. 干细胞移植治疗多发性骨髓瘤:目前和未来的状况。

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.3

S Giralt, W Bensinger

{"title":"Stem cell transplantation for multiple myeloma: current and future status.","authors":"S Giralt, W Bensinger","doi":"10.1038/leusup.2013.3","DOIUrl":"https://doi.org/10.1038/leusup.2013.3","url":null,"abstract":"Stem cell transplantation (SCT) has been used in the treatment of multiple myeloma (MM) for decades and has become a standard of care for newly diagnosed MM patients. However, several important questions remain regarding the optimal use of SCT, particularly in light of the many recent advances in the treatment of MM. Bortezomib-based therapy or, in some cases, lenalidomide-based therapy should be considered as an induction therapy in transplantation-eligible patients. Efforts to improve upon the efficacy and safety of standard transplantation regimens (that is, high-dose melphalan) are also underway. Most published studies on the use of tandem autologous SCT were conducted before the advent of novel agents, such as thalidomide, lenalidomide and bortezomib, making it difficult to establish the current role of tandem SCT. Allogeneic SCT continues to be evaluated in clinical trials, and may have an important role in the treatment of transplantation-eligible patients with suitable donors. Post-transplantation consolidation and maintenance therapy using novel agents should be considered to improve outcomes in patients who fail to achieve a complete response following SCT. Patients in remission should be advised that continued therapy has been shown to prolong remission, improve quality of life and extend survival. Additional data on the optimal approach to post-transplantation therapy are needed. New strategies in development aimed at improving patient selection, safety and efficacy of SCT are likely to improve future outcomes. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"2 Suppl 1","pages":"S10-4"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2013.3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34479561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Challenges in multiple myeloma diagnosis and treatment. 多发性骨髓瘤诊断和治疗的挑战。

Leukemia supplements Pub Date : 2013-05-01 Epub Date: 2013-05-08 DOI: 10.1038/leusup.2013.2

S Girnius, N C Munshi

{"title":"Challenges in multiple myeloma diagnosis and treatment.","authors":"S Girnius, N C Munshi","doi":"10.1038/leusup.2013.2","DOIUrl":"https://doi.org/10.1038/leusup.2013.2","url":null,"abstract":"Although multiple myeloma (MM) remains an incurable disease, the advent of novel treatment paradigms has improved survival outcomes in the past two decades. This includes widespread use of high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) and the development of the novel agents thalidomide, lenalidomide and bortezomib. The efficacy and tolerability of these novel agents have allowed for the exploration of continuous therapy approaches. Maintenance therapy after HDT-ASCT, for example, may help prolong progression-free survival by providing sustained control of residual disease. Trials are also under way to evaluate lenalidomide in patients with high-risk smoldering MM, with the aim of delaying progression to symptomatic MM. Other research is focusing on improving HDT-ASCT protocols and integrating novel agents, such as bortezomib, as an induction or consolidation therapy. Despite these advances, more effective strategies are needed, particularly for the management of older, less fit patients who are ineligible for HDT-ASCT. Preliminary results on the use of lenalidomide maintenance therapy in elderly patients are encouraging. Taken together, these observations indicate that in this era of novel agents, optimal treatment of MM requires a long-term perspective that focuses on providing sustained disease control while maintaining quality of life. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"2 Suppl 1","pages":"S3-9"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2013.2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34480552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. 化疗难治性慢性淋巴细胞白血病的基因组显示NOTCH1和SF3B1频繁突变。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.16

D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, S Cresta, R Famà, C Deambrogi, M Greco, M Fangazio, C Ciardullo, D Piranda, G M Casaluci, M Messina, I D Giudice, S Chiaretti, M Marinelli, A Guarini, R Foà, G Gaidano

{"title":"The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1.","authors":"D Rossi, S Rasi, V Spina, A Bruscaggin, S Monti, S Cresta, R Famà, C Deambrogi, M Greco, M Fangazio, C Ciardullo, D Piranda, G M Casaluci, M Messina, I D Giudice, S Chiaretti, M Marinelli, A Guarini, R Foà, G Gaidano","doi":"10.1038/leusup.2012.16","DOIUrl":"https://doi.org/10.1038/leusup.2012.16","url":null,"abstract":"Next-generation whole-exome sequencing has revealed two novel genes, namely NOTCH1 and SF3B1, whose mutations predict poor outcome and preferentially associate with chemorefractory chronic lymphocytic leukemia (CLL). Analysis of 539 CLL cases documents that NOTCH1 mutations i) represent one of the most frequent cancer gene mutations involved at presentation; ii) cluster with cases harboring trisomy 12 and tend to be mutually exclusive with TP53 disruption among genetic subgroups; iii) identify high-risk patients showing poor survival similar to that associated with TP53 abnormalities; and iv) exert a prognostic role independent of widely accepted clinical and genetic risk factors. Mutations of SF3B1, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL, occur at a low rate at CLL presentation and have a minor role in Richter transformation, corroborating the notion that CLL histological shift is molecularly distinct from chemorefractory progression without the Richter transformation. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S26-8"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34544518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. 未来十年的挑战:异基因干细胞移植治疗慢性淋巴细胞白血病。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.19

P Corradini, L Farina

引用次数: 0

Initial treatment for patients with chronic myeloid leukemia. 慢性髓性白血病患者的初始治疗。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.21

M Baccarani

引用次数: 0

Advances in unrelated cord blood transplants in malignancies. 非亲属脐带血移植治疗恶性肿瘤的研究进展。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.8

E Gluckman

{"title":"Advances in unrelated cord blood transplants in malignancies.","authors":"E Gluckman","doi":"10.1038/leusup.2012.8","DOIUrl":"https://doi.org/10.1038/leusup.2012.8","url":null,"abstract":"Cord blood is an unlimited source of hematopoietic stem cells (HSCs) for allogeneic HSC transplant. Since the first human cord blood transplant performed 20 years ago, cord blood banks have been established worldwide for collection and cryopreservation of cord blood for allogeneic HSC transplant. More than 500 000 cord blood units are now available for international exchange of cord blood units. A global network of cord blood banks and transplant centers has been established for a common inventory and study of clinical outcomes. Results of unrelated allogeneic cord blood transplants in malignant and nonmalignant diseases, in adults and children, show that, compared with HLA-matched unrelated bone marrow transplant, cord blood has several advantages including prompt availability of the transplant, decrease of graft versus host disease and better long-term immune recovery resulting in a similar long-term survival. Several studies have shown that the number of cells is the most important factor for engraftment while some degree of HLA mismatches is acceptable. Progresses in this field are expected to facilitate engraftment including ex vivo expansion of stem cells, intra-bone injection of cord blood cells and double cord blood transplants. ","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S10-1"},"PeriodicalIF":0.0,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34481279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Modern therapy of young and adult Ph-ALL. 青年和成人Ph-ALL的现代治疗。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.6

R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi

引用次数: 2

Normal and leukemic stem cells. 正常和白血病干细胞。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.27

P G Pelicci

引用次数: 4

Chronic lymphocytic leukemia: treatment of relapse. 慢性淋巴细胞白血病:复发的治疗。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.18

M Montillo

引用次数: 1

Change in prognostic factors. 预后因素的改变。

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI: 10.1038/leusup.2012.4

D Hoelzer, N Gökbuget

引用次数: 6